Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment: diagnostic and prognostic impact

IF 13.4 1区医学 Q1 HEMATOLOGY

Leukemia Pub Date : 2025-08-07 DOI:10.1038/s41375-025-02717-0

Bastien Jamet, Cyrille Touzeau, Hatem Necib, Éric Frampas, Huajun Sun, Chloe Francois, Nicolas Blin, Thomas Carlier, Aurélien Monnet, Nicoletta Lilli, Caroline Bodet-Milin, Philippe Moreau, Françoise Kraeber-Bodere

{"title":"Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment: diagnostic and prognostic impact","authors":"Bastien Jamet, Cyrille Touzeau, Hatem Necib, Éric Frampas, Huajun Sun, Chloe Francois, Nicolas Blin, Thomas Carlier, Aurélien Monnet, Nicoletta Lilli, Caroline Bodet-Milin, Philippe Moreau, Françoise Kraeber-Bodere","doi":"10.1038/s41375-025-02717-0","DOIUrl":null,"url":null,"abstract":"The co-primary aims of this study were to assess the diagnostic and prognostic performance of Whole-body-2-[18F]-fluorodeoxyglucose-positron emission tomography coupled with MRI (WB-2-[18F]FDG-PET/MRI) imaging in the smoldering multiple myeloma (SMM) workup for detection of MM-related medullary or extra-medullary disease and for the prediction of progression-free survival (PFS) defined as time to progression to symptomatic MM requiring therapy. A total of 116 patients with SMM (without CRAB or SLiM criteria before imaging) were prospectively included in the study and underwent full multi-parametric WB-2-[18F]FDG-PET/MRI imaging. PET detected at least one FL > 5 mm in 9% of patients compared to 20% on MRI (p = 0.02). PET detected diffuse bone marrow involvement (BMI) in 20% of patients and MRI in 53% (p < 10−3). A total of 98 patients with true SMM not requiring treatment were then followed up. The presence of diffuse BMI on MRI was the strongest adverse prognostic parameter for PFS (univariate: hazard ratio (HR), 6.12; p < 10−2. Multivariate : HR, 4.16; p = 0.03) and could be proposed as a new high-risk biomarker for progression to symptomatic MM. Dynamic contrast-enhanced (DCE)-MRI based increased peak enhancement intensity (PEI) and maximum intensity time ratio (MITR) values were other strong adverse prognostic factors.","PeriodicalId":18109,"journal":{"name":"Leukemia","volume":"39 10","pages":"2516-2522"},"PeriodicalIF":13.4000,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41375-025-02717-0","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The co-primary aims of this study were to assess the diagnostic and prognostic performance of Whole-body-2-[18F]-fluorodeoxyglucose-positron emission tomography coupled with MRI (WB-2-[18F]FDG-PET/MRI) imaging in the smoldering multiple myeloma (SMM) workup for detection of MM-related medullary or extra-medullary disease and for the prediction of progression-free survival (PFS) defined as time to progression to symptomatic MM requiring therapy. A total of 116 patients with SMM (without CRAB or SLiM criteria before imaging) were prospectively included in the study and underwent full multi-parametric WB-2-[18F]FDG-PET/MRI imaging. PET detected at least one FL > 5 mm in 9% of patients compared to 20% on MRI (p = 0.02). PET detected diffuse bone marrow involvement (BMI) in 20% of patients and MRI in 53% (p < 10−3). A total of 98 patients with true SMM not requiring treatment were then followed up. The presence of diffuse BMI on MRI was the strongest adverse prognostic parameter for PFS (univariate: hazard ratio (HR), 6.12; p < 10−2. Multivariate : HR, 4.16; p = 0.03) and could be proposed as a new high-risk biomarker for progression to symptomatic MM. Dynamic contrast-enhanced (DCE)-MRI based increased peak enhancement intensity (PEI) and maximum intensity time ratio (MITR) values were other strong adverse prognostic factors.

Abstract Image

查看原文本刊更多论文

同时全身多参数2-[18F]FDG-PET/MRI在阴燃型多发性骨髓瘤评估中的应用：诊断和预后影响

本研究的共同主要目的是评估全身2-[18F]-氟脱氧葡萄糖-正电子发射断层扫描结合MRI （WB-2-[18F]FDG-PET/MRI）成像在阴燃多发性骨髓瘤（SMM）检查中的诊断和预后表现，以检测MM相关的髓质或髓外疾病，并预测无进展生存期（PFS）， PFS定义为进展到需要治疗的症状性MM的时间。共116例SMM患者（成像前无CRAB或SLiM标准）被前瞻性纳入研究，并进行了完整的多参数WB-2-[18F]FDG-PET/MRI成像。PET在9%的患者中检测到至少一个FL >； 5 mm，而MRI为20% （p = 0.02）。PET检测到弥漫性骨髓受累（BMI）的患者占20%，MRI检测到弥漫性骨髓受累的患者占53% （p < 10−3）。对98例不需治疗的真性SMM患者进行随访。MRI上弥漫性BMI的存在是PFS最强的不良预后参数(单因素：风险比（HR）， 6.12；p < 10−2；多因素：HR， 4.16；p = 0.03)，可以作为进展为症状性MM的新的高风险生物标志物。基于动态对比增强(DCE)-MRI的峰值增强强度（PEI）和最大强度时间比（MITR）值的增加是其他强烈的不良预后因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Leukemia 医学-血液学

CiteScore

18.10

自引率

3.50%

发文量

270

审稿时长

3-6 weeks

期刊介绍： Title: Leukemia Journal Overview: Publishes high-quality, peer-reviewed research Covers all aspects of research and treatment of leukemia and allied diseases Includes studies of normal hemopoiesis due to comparative relevance Topics of Interest: Oncogenes Growth factors Stem cells Leukemia genomics Cell cycle Signal transduction Molecular targets for therapy And more Content Types: Original research articles Reviews Letters Correspondence Comments elaborating on significant advances and covering topical issues